Mephedrone (4-methylmethcathinone) and d-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques

British Journal of Pharmacology

Volumn 167, Issue 6, 2012, Pages 1342-1352

  Wright, M J ^a   Vandewater, S A ^a   Angrish, D ^a   Dickerson, T J ^a   Taffe, M A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

cathinone; learning; Macaca mulatta; memory; stimulant

Indexed keywords

4' METHYLMETHCATHINONE; METHAMPHETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATIVE MEMORY; CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY; CONTROLLED STUDY; DEPTH PERCEPTION; DOSE RESPONSE; EXPERIMENTAL MONKEY; EYE TRACKING; LEARNING; MALE; MOTIVATION; MOTOR COORDINATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REWARD; RHESUS MONKEY; SPATIAL MEMORY; STIMULUS RESPONSE; TASK PERFORMANCE; WORKING MEMORY;

EID: 84865628130     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02091.x     Document Type: Article

References (39)

1. Baron SP, Wenger GR, (2001). Effects of drugs of abuse on response accuracy and bias under a delayed matching-to-sample procedure in squirrel monkeys. Behav Pharmacol 12: 247-256.
2. Bauer RH, Fuster JM, (1978). Effects of d-amphetamine and prefrontal cortical cooling on delayed matching-to-sample behavior. Pharmacol Biochem Behav 8: 243-249.
3. Baumann MH, Wang X, Rothman RB, (2007). 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189: 407-424.
4. Baumann MH, Clark RD, Rothman RB, (2008). Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav 90: 208-217.
5. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al,. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
6. Bluelight (2008). (RC's) Big mephedrone thread. Vol. 2010.
7. Camilleri A, Johnston MR, Brennan M, Davis S, Caldicott DG, (2010). Chemical analysis of four capsules containing the controlled substance analogs 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci Int 197: 56-66.
8. Clark JD, Baldwin RL, Bayne KA, Brown MJ, Gebhart GF, Gonder JC, et al,. (1996). Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, National Research Council: Washington, DC.
9. Crean RD, Vandewater SA, Katner SN, Huitron-Resendiz S, Taffe MA, (2011). Chronic alcohol consumption impairs visuo-spatial associative memory in periadolescent rhesus monkeys. Drug Alcohol Depend 114: 31-40.
10. DEA (2011a). Request for information on synthetic cathinones. Microgram Bull 44: 31-34.
11. DEA (2011b). Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. Fed Regist 76: 65371-65375.
12. Freeman TP, Morgan CJ, Vaughn-Jones J, Hussain N, Karimi K, Curran HV, (2012). Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 107: 792-800.
13. Geezaman DF, (2009). Surprisingly like E. In: Erowid Experience Vaults, Vol. 2010.
14. Gold LH, Koob GF, Geyer MA, (1988). Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther 247: 547-555.
15. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508.
16. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al,. (2011). 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
17. Huang P-K, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA, (2012). Contrasting effects of d-methamphetamine, 3,4- methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend. doi: 10.1016/j.drugalcdep.2012.05.011. Epub ahead of print.
18. Iversen L, Adebowale V, Abdulrahim D, Arr-Jones G, Barnes M, Birtwistle M, et al,. (2010). Consideration of the Cathinones. Advisory Council on the Misuse of Drugs: London, UK.
19. Katner SN, Davis SA, Kirsten AJ, Taffe MA, (2004a). Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology (Berl) 175: 225-240.
20. Katner SN, Flynn CT, Von Huben SN, Kirsten AJ, Davis SA, Lay CC, et al,. (2004b). Controlled and behaviorally relevant levels of oral ethanol intake in rhesus macaques using a flavorant-fade procedure. Alcohol Clin Exp Res 28: 873-883.
21. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al,. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
23. Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL, (2012). A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 219: 109-122.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS, (2012). Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17: 409-422.
26. Rupniak NM, Samson NA, Steventon MJ, Iversen SD, (1991). Induction of cognitive impairment by scopolamine and noncholinergic agents in rhesus monkeys. Life Sci 48: 893-899.
27. Schulze GE, Paule MG, (1990). Acute effects of d-amphetamine in a monkey operant behavioral test battery. Pharmacol Biochem Behav 35: 759-765.
28. Sedefov R, Solberg U, Gallegos A, Almeida A, (2010). Europol-EMCDDA Joint Report on a New Psychoactive Substance: 4-Methylmethcathinone (Mephedrone). European Monitoring Centre for Drugs and Drug Addiction: Lisbon, Portugal.
29. Taffe MA, Weed MR, Gold LH, (1999). Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res 8: 203-212.
30. Taffe MA, Davis SA, Gutierrez T, Gold LH, (2002a). Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend 68: 175-187.
31. Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH, (2002b). Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys. Psychopharmacology (Berl) 160: 253-262.
32. Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH, (2004). Modeling a task that is sensitive to dementia of the Alzheimer's type: individual differences in acquisition of a visuo-spatial paired-associate learning task in rhesus monkeys. Behav Brain Res 149: 123-133.
33. Verrico CD, Lynch L, Fahey MA, Fryer AK, Miller GM, Madras BK, (2008). MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol 22: 187-202.
34. Von Huben SN, Davis SA, Lay CC, Katner SN, Crean RD, Taffe MA, (2006). Differential contributions of dopaminergic D(1)- and D(2)-like receptors to cognitive function in rhesus monkeys. Psychopharmacology (Berl) 188: 586-596.
35. Weed MR, Taffe MA, Polis I, Roberts AC, Robbins TW, Koob GF, et al,. (1999). Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Cogn Brain Res 8: 184-201.
36. Winstock A, Mitcheson L, Marsden J, (2010). Mephedrone: still available and twice the price. Lancet 376: 1537-1537.
37. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J, (2011a). Mephedrone: use, subjective effects and health risks. Addiction 106: 1991-1996.
38. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F, (2011b). Mephedrone, new kid for the chop? Addiction 106: 154-161.
39. Yerkes RM, Dodson JD, (1908). The relation of strength of stimulus to rapidity of habit-formation. J Comp Neurol Psychol 18: 459-482.